Top

Published in:

13-04-2023 | Heart Surgery | Review

Drugs in treating paediatric acute kidney injury

Authors: Caoimhe Costigan, Steve Balgobin, Michael Zappitelli

Published in: Pediatric Nephrology | Issue 12/2023

Abstract

Acute kidney injury (AKI) is a complex syndrome which affects a significant proportion of hospitalized children. The breadth and impact of AKI on health outcomes in both adults and children have come to the fore in recent years with increasing awareness encouraging research advancement. Despite this, management strategies for most types of AKI remain heavily reliant on fluid and electrolyte management, hemodynamic optimization, nephrotoxin avoidance and appropriate initiation of kidney replacement therapy. Specific drugs targeting the mechanisms involved in AKI remain elusive. Recent improvement in appreciation of the complexity of AKI pathophysiology has allowed for greater opportunity to consider novel therapeutic agents. A number of drugs specifically targeting AKI are in various stages of development. This review will consider some novel and repurposed agents; interrogate the plausibility of the proposed mechanisms of action, as they relate to what we know about the pathophysiology of AKI; and review the level of existing literature supporting their efficacy. The evidence base, particularly in children, is limited.

McGregor TL, Jones DP, Wang L, Danciu I et al (2016) Acute kidney injury incidence in noncritically ill hospitalized children, adolescents, and young adults: a retrospective observational study. Am J Kidney Dis 67:384–390PubMed

Kaddourah A, Basu RK, Bagshaw SM, Goldstein SL et al (2017) Epidemiology of acute kidney injury in critically ill children and young adults. N Engl J Med 376:11–20PubMed

Khwaja A (2012) KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 120:c179-184PubMed

Hessey E, Melhem N, Alobaidi R, Ulrich E et al (2021) Acute kidney injury in critically ill children is not all acute: lessons over the last 5 years. Front Pediatr 9:648587PubMedPubMedCentral

Devarajan P (2022) Pathogenesis of intrinsic acute kidney injury. Curr Opin Pediatr 35:234–238PubMed

Benoit SW, Devarajan P (2018) Acute kidney injury: emerging pharmacotherapies in current clinical trials. Pediatr Nephrol 33:779–787PubMed

Castaneda MP, Swiatecka-Urban A, Mitsnefes MM, Feuerstein D et al (2003) Activation of mitochondrial apoptotic pathways in human renal allografts after ischemiareperfusion injury. Transplantation 76:50–54PubMed

Baliga R, Ueda N, Walker PD, Shah SV (1999) Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev 31:971–997PubMed

Vallon V (2003) Tubuloglomerular feedback and the control of glomerular filtration rate. News Physiol Sci 18:169–174PubMed

10.

Schmidt C, Hocherl K, Schweda F, Bucher M (2007) Proinflammatory cytokines cause down-regulation of renal chloride entry pathways during sepsis. Crit Care Med 35:2110–2119PubMed

11.

Venkatachalam MA, Weinberg JM, Kriz W, Bidani AK (2015) Failed tubule recovery, AKI-CKD transition, and kidney disease progression. J Am Soc Nephrol 26:1765–1776PubMedPubMedCentral

12.

Brocklebank V, Wood KM, Kavanagh D (2018) Thrombotic microangiopathy and the kidney. Clin J Am Soc Nephrol 13:300–317PubMed

13.

Raghavan R, Eknoyan G (2014) Acute interstitial nephritis - a reappraisal and update. Clin Nephrol 82:149–162PubMedPubMedCentral

14.

Davidson JA, Khailova L, Treece A, Robison J et al (2019) Alkaline phosphatase treatment of acute kidney injury in an infant piglet model of cardiopulmonary bypass with deep hypothermic circulatory arrest. Sci Rep 9:14175PubMedPubMedCentral

15.

Peters E, Geraci S, Heemskerk S, Wilmer MJ et al (2015) Alkaline phosphatase protects against renal inflammation through dephosphorylation of lipopolysaccharide and adenosine triphosphate. Br J Pharmacol 172:4932–4945PubMedPubMedCentral

16.

Heemskerk S, Masereeuw R, Moesker O, Bouw MP et al (2009) Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients. Crit Care Med 37:417 423-e411

17.

Pickkers P, Heemskerk S, Schouten J, Laterre PF et al (2012) Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial. Crit Care 16:R14PubMedPubMedCentral

18.

Pickkers P, Mehta RL, Murray PT, Joannidis M et al (2018) Effect of human recombinant alkaline phosphatase on 7-day creatinine clearance in patients with sepsis-associated acute kidney injury: a randomized clinical trial. JAMA 320:1998–2009PubMedPubMedCentral

19.

Kohda Y, Chiao H, Star RA (1998) alpha-Melanocyte-stimulating hormone and acute renal failure. Curr Opin Nephrol Hypertens 7:413–417PubMed

20.

Simmons MN, Subramanian V, Crouzet S, Haber GP et al (2010) Alpha-melanocyte stimulating hormone analogue AP214 protects against ischemia induced acute kidney injury in a porcine surgical model. J Urol 183:1625–1629PubMed

21.

McCullough PA, Bennett-Guerrero E, Chawla LS, Beaver T et al (2016) ABT-719 for the prevention of acute kidney injury in patients undergoing high-risk cardiac surgery: a randomized phase 2b clinical trial. J Am Heart Assoc 5:e003549PubMedPubMedCentral

22.

Zhuo M, Paik JM, Wexler DJ, Bonventre JV et al (2022) SGLT2 inhibitors and the risk of acute kidney injury in older adults with type 2 diabetes. Am J Kidney Dis 79:858-867-e851

23.

Higashijima Y, Tanaka T, Yamaguchi J, Tanaka S et al (2015) Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury. Am J Physiol Renal Physiol 308:F878-887PubMed

24.

Katagiri D, Hamasaki Y, Doi K, Okamoto K et al (2013) Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection. J Am Soc Nephrol 24:2034–2043PubMedPubMedCentral

25.

Thielmann M, Corteville D, Szabo G, Swaminathan M et al (2021) Teprasiran, a small interfering RNA, for the prevention of acute kidney injury in high-risk patients undergoing cardiac surgery: a randomized clinical study. Circulation 144:1133–1144PubMedPubMedCentral

26.

Kaushal GP, Shah SV (2016) Autophagy in acute kidney injury. Kidney Int 89:779–791PubMedPubMedCentral

27.

Andrianova NV, Zorova LD, Babenko VA, Pevzner IB et al (2019) Rapamycin is not protective against ischemic and cisplatin-induced kidney injury. Biochemistry (Mosc) 84:1502–1512PubMed

28.

Su Y, Lu J, Gong P, Chen X et al (2018) Rapamycin induces autophagy to alleviate acute kidney injury following cerebral ischemia and reperfusion via the mTORC1/ATG13/ULK1 signaling pathway. Mol Med Rep 18:5445–5454PubMedPubMedCentral

29.

Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R et al (2012) Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149:1060–1072PubMedPubMedCentral

30.

Maremonti F, Meyer C, Linkermann A (2022) Mechanisms and models of kidney tubular necrosis and nephron loss. J Am Soc Nephrol 33:472–486PubMedPubMedCentral

31.

Devisscher L, Van Coillie S, Hofmans S, Van Rompaey D et al (2018) Discovery of novel, drug-like ferroptosis inhibitors with in vivo efficacy. J Med Chem 61:10126–10140PubMed

32.

Sharma S, Leaf DE (2019) Iron chelation as a potential therapeutic strategy for AKI prevention. J Am Soc Nephrol 30:2060–2071PubMedPubMedCentral

33.

Mishra OP, Pooniya V, Ali Z, Upadhyay RS et al (2008) Antioxidant status of children with acute renal failure. Pediatr Nephrol 23:2047–2051PubMed

34.

Bolisetty S, Zarjou A, Agarwal A (2017) Heme oxygenase 1 as a therapeutic target in acute kidney injury. Am J Kidney Dis 69:531–545PubMedPubMedCentral

35.

Carlson WD, Keck PC, Bosukonda D, Carlson FR Jr (2022) A process for the design and development of novel bone morphogenetic protein-7 (BMP-7) mimetics with an example: THR-184. Front Pharmacol 13:864509PubMedPubMedCentral

36.

Wetzel P, Haag J, Campean V, Goldschmeding R et al (2006) Bone morphogenetic protein-7 expression and activity in the human adult normal kidney is predominantly localized to the distal nephron. Kidney Int 70:717–723PubMed

37.

Himmelfarb J, Chertow GM, McCullough PA, Mesana T et al (2018) Perioperative THR-184 and AKI after cardiac surgery. J Am Soc Nephrol 29:670–679PubMed

38.

Vincenti F, Kim J, Gouveia D, Pelle G et al (2021) Phase 3 trial design of the hepatocyte growth factor mimetic ANG-3777 in renal transplant recipients with delayed graft function. Kidney Int Rep 6:296–303PubMed

39.

Swaminathan M, Stafford-Smith M, Chertow GM, Warnock DG et al (2018) Allogeneic mesenchymal stem cells for treatment of AKI after cardiac surgery. J Am Soc Nephrol 29:260–267PubMed

40.

Bove T, Zangrillo A, Guarracino F, Alvaro G et al (2014) Effect of fenoldopam on use of renal replacement therapy among patients with acute kidney injury after cardiac surgery: a randomized clinical trial. JAMA 312:2244–2253PubMed

41.

Noce A, Marrone G, Rovella V, Busca A et al (2019) Fenoldopam mesylate: a narrative review of its use in acute kidney injury. Curr Pharm Biotechnol 20:366–375PubMedPubMedCentral

42.

Gillies MA, Kakar V, Parker RJ, Honore PM et al (2015) Fenoldopam to prevent acute kidney injury after major surgery-a systematic review and meta-analysis. Crit Care 19:449PubMedPubMedCentral

43.

Ricci Z, Luciano R, Favia I, Garisto C et al (2011) High-dose fenoldopam reduces postoperative neutrophil gelatinase-associated lipocaline and cystatin C levels in pediatric cardiac surgery. Crit Care 15:R160PubMedPubMedCentral

44.

Nakagawa Y, Nishikimi T, Kuwahara K (2019) Atrial and brain natriuretic peptides: Hormones secreted from the heart. Peptides 111:18–25PubMed

45.

Zeidel ML (1990) Renal actions of atrial natriuretic peptide: regulation of collecting duct sodium and water transport. Annu Rev Physiol 52:747–759PubMed

46.

Nigwekar SU, Navaneethan SD, Parikh CR, Hix JK (2009) Atrial natriuretic peptide for management of acute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol 4:261–272PubMedPubMedCentral

47.

Yamada H, Doi K, Tsukamoto T, Kiyomoto H et al (2019) Low-dose atrial natriuretic peptide for prevention or treatment of acute kidney injury: a systematic review and meta-analysis. Crit Care 23:41PubMedPubMedCentral

48.

Sackner-Bernstein JD, Skopicki HA, Aaronson KD (2005) Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111:1487–1491PubMed

49.

van Deursen VM, Hernandez AF, Stebbins A, Hasselblad V et al (2014) Nesiritide, renal function, and associated outcomes during hospitalization for acute decompensated heart failure: results from the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF). Circulation 130:958–965PubMed

50.

Ejaz AA, Martin TD, Johnson RJ, Winterstein AG et al (2009) Prophylactic nesiritide does not prevent dialysis or all-cause mortality in patients undergoing high-risk cardiac surgery. J Thorac Cardiovasc Surg 138:959–964PubMed

51.

Bronicki RA, Domico M, Checchia PA, Kennedy CE et al (2017) The use of nesiritide in children with congenital heart disease. Pediatr Crit Care Med 18:151–158PubMed

52.

Campbell DJ (2017) Long-term neprilysin inhibition - implications for ARNIs. Nat Rev Cardiol 14:171–186PubMed

53.

Packer M, Claggett B, Lefkowitz MP, McMurray JJV et al (2018) Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol 6:547–554PubMed

54.

Voors AA, Gori M, Liu LC, Claggett B et al (2015) Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 17:510–517PubMed

55.

Kemna M, Hong B, Friedland-Little J, Albers E, Law YM (2020) Valsartan/sacubitril in pediatric heart failure. J Heart Lung Transplant 39:S450

56.

Bhatt GC, Gogia P, Bitzan M, Das RR (2019) Theophylline and aminophylline for prevention of acute kidney injury in neonates and children: a systematic review. Arch Dis Child 104:670–679PubMed

57.

Alsaadoun S, Rustom F, Hassan HA, Alkhurais H et al (2020) Aminophylline for improving acute kidney injury in pediatric patients: a systematic review and meta-analysis. Int J Health Sci (Qassim) 14:44–51PubMed

58.

Gordon AC, Perkins GD, Singer M, McAuley DF et al (2016) Levosimendan for the prevention of acute organ dysfunction in sepsis. N Engl J Med 375:1638–1648PubMed

59.

Joannidis M, Druml W, Forni LG, Groeneveld ABJ et al (2017) Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017: Expert opinion of the Working Group on Prevention, AKI section, European Society of Intensive Care Medicine. Intensive Care Med 43:730–749PubMedPubMedCentral

60.

Thorlacius EM, Suominen PK, Wahlander H, Keski-Nisula J et al (2019) The effect of levosimendan versus milrinone on the occurrence rate of acute kidney injury following congenital heart surgery in infants: a randomized clinical trial. Pediatr Crit Care Med 20:947–956PubMed

61.

Grisaru S, Xie J, Samuel S, Hartling L et al (2017) Associations between hydration status, intravenous fluid administration, and outcomes of patients infected with Shiga toxin-producing Escherichia coli: a systematic review and meta-analysis. JAMA Pediatr 171:68–76PubMed

62.

Legendre CM, Licht C, Muus P, Greenbaum LA et al (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368:2169–2181PubMed

63.

Schoettler M, Carreras E, Cho B, Dandoy CE et al (2022) Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research. Transplant Cell Ther 29:151–163PubMedPubMedCentral

64.

Barbour T, Scully M, Ariceta G, Cataland S et al (2021) Long-term efficacy and safety of the long-acting complement C5 inhibitor ravulizumab for the treatment of atypical hemolytic uremic syndrome in adults. Kidney Int Rep 6:1603–1613PubMedPubMedCentral

65.

Tanaka K, Adams B, Aris AM, Fujita N et al (2021) The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab. Pediatr Nephrol 36:889–898PubMed

66.

Goodship TH, Cook HT, Fakhouri F, Fervenza FC et al (2017) Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int 91:539–551PubMed

67.

Andrianova NV, Zorov DB, Plotnikov EY (2020) Targeting inflammation and oxidative stress as a therapy for ischemic kidney injury. Biochemistry (Mosc) 85:1591–1602PubMed

68.

Clave S, Rousset-Rouviere C, Daniel L, Tsimaratos M (2019) The invisible threat of non-steroidal anti-inflammatory drugs for kidneys. Front Pediatr 7:520PubMedPubMedCentral

69.

Saran R, Robinson B, Abbott KC, Bragg-Gresham J et al (2020) US Renal Data System 2019 Annual Data Report: epidemiology of kidney disease in the United States. Am J Kidney Dis 75:A6–A7PubMed

70.

Raza MN, Hadid M, Keen CE, Bingham C et al (2012) Acute tubulointerstitial nephritis, treatment with steroid and impact on renal outcomes. Nephrology (Carlton) 17:748–753PubMed

71.

Ulinski T, Sellier-Leclerc AL, Tudorache E, Bensman A et al (2012) Acute tubulointerstitial nephritis. Pediatr Nephrol 27:1051–1057PubMed

72.

Jahnukainen T, Saarela V, Arikoski P, Ylinen E et al (2013) Prednisone in the treatment of tubulointerstitial nephritis in children. Pediatr Nephrol 28:1253–1260PubMed

73.

Fernandez-Juarez G, Perez JV, Caravaca-Fontan F, Quintana L et al (2018) Duration of treatment with corticosteroids and recovery of kidney function in acute interstitial nephritis. Clin J Am Soc Nephrol 13:1851–1858PubMedPubMedCentral

74.

Wente-Schulz S, Aksenova M, Awan A, Ambarsari CG et al (2021) Aetiology, course and treatment of acute tubulointerstitial nephritis in paediatric patients: a cross-sectional web-based survey. BMJ Open 11:e047059PubMedPubMedCentral

75.

Tirelli F, Shafer BM, Davidson SL, Lerman MA (2021) Immunomodulation and TNF-alpha inhibition for tubulointerstitial nephritis and uveitis syndrome: a case series. J AAPOS 25:267.e1-267.e6PubMed

76.

Moledina DG, Wilson FP, Kukova L, Obeid W et al (2021) Urine interleukin-9 and tumor necrosis factor-alpha for prognosis of human acute interstitial nephritis. Nephrol Dial Transplant 36:1851–1858PubMed

77.

Hulse M, Rosner MH (2019) Drugs in development for acute kidney injury. Drugs 79:811–821PubMed

78.

Kalantari K, Rosner MH (2021) Recent advances in the pharmacological management of sepsis-associated acute kidney injury. Expert Rev Clin Pharmacol 14:1401–1411PubMed

79.

Pickkers P, Darmon M, Hoste E, Joannidis M et al (2021) Acute kidney injury in the critically ill: an updated review on pathophysiology and management. Intensive Care Med 47:835–850PubMedPubMedCentral

80.

Xu Y, Zou P, Cao X (2022) Advances in pharmacotherapy for acute kidney injury. Expert Opin Pharmacother 23:713–726PubMed

81.

Endre ZH, Kellum JA, Di Somma S, Doi K et al (2013) Differential diagnosis of AKI in clinical practice by functional and damage biomarkers: workgroup statements from the tenth Acute Dialysis Quality Initiative Consensus Conference. Contrib Nephrol 182:30–44PubMed

82.

Goldstein SL, Akcan-Arikan A, Alobaidi R, Askenazi DJ et al (2022) Consensus-based recommendations on priority activities to address acute kidney injury in children: a modified Delphi consensus statement. JAMA Netw Open 5:e2229442PubMedPubMedCentral

83.

Iwakura T, Fukasawa H, Kitamura A, Ishibuchi K et al (2020) Effect of dipeptidyl peptidase-4 inhibitors on cisplatin-induced acute nephrotoxicity in cancer patients with diabetes mellitus: a retrospective study. PLoS One 15:e0229377

84.

Ambrosi N, Arrosagaray V, Guerrieri D, Uva PD et al (2016) alpha-lipoic acid protects against ischemia-reperfusion injury in simultaneous kidney-pancreas transplantation. Transplantation 100:908–915PubMed

85.

Suh SH, Lee KE, Kim IJ, Kim O et al (2015) Alpha-lipoic acid attenuates lipopolysaccharide-induced kidney injury. Clin Exp Nephrol 19:82–91PubMed

86.

Du J, Jiang S, Hu Z, Tang S et al (2019) Vitamin D receptor activation protects against lipopolysaccharide-induced acute kidney injury through suppression of tubular cell apoptosis. Am J Physiol Renal Physiol 316:F1068–F1077PubMed

87.

Bulger EM, May AK, Robinson BRH, Evans DC et al (2020) A novel immune modulator for patients with necrotizing soft tissue infections (NSTI): results of a multicenter, phase 3 randomized controlled trial of reltecimod (AB 103). Ann Surg 272:469–478PubMed

88.

Garg AX, Devereaux PJ, Hill A, Sood M et al (2018) Oral curcumin in elective abdominal aortic aneurysm repair: a multicentre randomized controlled trial. CMAJ 190:E1273–E1280PubMedPubMedCentral

89.

Correa TD, Takala J, Jakob SM (2015) Angiotensin II in septic shock. Crit Care 19:98PubMedPubMedCentral

90.

Wan L, Langenberg C, Bellomo R, May CN (2009) Angiotensin II in experimental hyperdynamic sepsis. Crit Care 13:R190PubMedPubMedCentral

91.

Friedrich JO, Adhikari N, Herridge MS, Beyene J (2005) Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 142:510–524PubMed

92.

Baysal A, Yanartas M, Dogukan M, Gundogus N et al (2014) Levosimendan improves renal outcome in cardiac surgery: a randomized trial. J Cardiothorac Vasc Anesth 28:586–594PubMed

93.

Zhou C, Gong J, Chen D, Wang W et al (2016) Levosimendan for prevention of acute kidney injury after cardiac surgery: a meta-analysis of randomized controlled trials. Am J Kidney Dis 67:408–416PubMed

94.

Loomba RS, Villarreal EG, Dhargalkar J, Rausa J et al (2022) The effect of dexmedetomidine on renal function after surgery: a systematic review and meta-analysis. J Clin Pharm Ther 47:287–297PubMed

95.

Ma S, Evans RG, Iguchi N, Tare M et al (2019) Sepsis-induced acute kidney injury: a disease of the microcirculation. Microcirculation 26:e12483PubMed

96.

Peng K, McIlroy DR, Bollen BA, Billings FTt, et al (2022) Society of cardiovascular anesthesiologists clinical practice update for management of acute kidney injury associated with cardiac surgery. Anesth Analg 135:744–756PubMed

97.

Xie Y, Jiang W, Cao J, Xie H (2021) Dexmedetomidine attenuates acute kidney injury in children undergoing congenital heart surgery with cardiopulmonary bypass by inhibiting the TLR3/NF-kappaB signaling pathway. Am J Transl Res 13:2763–2773PubMedPubMedCentral

98.

Poyan Mehr A, Tran MT, Ralto KM, Leaf DE et al (2018) De novo NAD(+) biosynthetic impairment in acute kidney injury in humans. Nat Med 24:1351–1359PubMed

Title: Drugs in treating paediatric acute kidney injury
Authors: Caoimhe Costigan
Steve Balgobin
Michael Zappitelli
Publication date: 13-04-2023
Publisher: Springer Berlin Heidelberg
Keywords: Heart Surgery
Acute Kidney Injury
Heart Surgery
Acute Kidney Injury
Growth Factors
Growth Factors
Published in: Pediatric Nephrology / Issue 12/2023
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-023-05956-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Drugs in treating paediatric acute kidney injury

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2023

Metabolic acidosis in pediatric kidney transplant recipients

Successful treatment with avacopan (CCX168) in a pediatric patient with C3 glomerulonephritis

Angiotensin II type 1 receptor antibodies and native kidney function in pediatric liver and intestinal transplant recipients

The first randomized controlled trial in pediatric nephrology: the history of the International Study of Kidney Disease in Children (ISKDC)

Evaluating the impact of accessible low-cost pediatric genetic testing on underserved communities in the United States

Trajectories of eGFR and risk of albuminuria in youth with type 2 diabetes: results from the TODAY cohort study